PKCβ has attracted immense attention as a therapeutic target in MM [22,23]; however, in clinical trials, treatment with the oral inhibitor enzastaurin showed no clinical benefit in patients with MM [24]. Here, PRKCB is linked to Miyoshi myopathy.